Reaction
Catheter Placement reporting signals
As of the last recalculation, Catheter Placement appears in 1,838 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 257.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoprostenol | 256 | 257.1 | 262.3 |
| Macitentan | 176 | 31.7 | 31.8 |
| Tadalafil | 185 | 23.2 | 23.2 |
| Sildenafil Powder, | 70 | 23.1 | 23.2 |
| Bosentan | 96 | 22.7 | 22.7 |
| Selexipag | 49 | 22.0 | 22.1 |
| Sildenafil | 100 | 20.6 | 20.7 |
| Ambrisentan | 195 | 19.7 | 19.7 |
| Sildenafil Citrate | 189 | 18.6 | 18.7 |
| Treprostinil | 180 | 17.9 | 17.9 |
| Paricalcitol | 22 | 17.8 | 17.9 |
| Agalsidase Beta | 14 | 17.3 | 17.3 |
| Riociguat | 42 | 14.9 | 14.9 |
| Ranolazine | 11 | 12.0 | 12.0 |
| Relugolix | 24 | 11.7 | 11.7 |
| Patiromer | 13 | 10.7 | 10.7 |
| Eculizumab | 50 | 10.7 | 10.7 |
| 0Xygen | 45 | 10.6 | 10.6 |
| Oxygen | 45 | 10.6 | 10.6 |
| Methimazole | 6 | 8.7 | 8.7 |
| Warfarin | 83 | 7.7 | 7.7 |
| Trifluridine And Tipiracil | 6 | 6.4 | 6.4 |
| Teduglutide | 7 | 5.9 | 5.9 |
| Panitumumab | 8 | 5.8 | 5.8 |
| Darbepoetin Alfa | 27 | 5.7 | 5.7 |
| Vibegron | 4 | 5.7 | 5.7 |
| Fesoterodine Fumarate | 5 | 5.2 | 5.2 |
| Abiraterone | 6 | 5.0 | 5.0 |
| Natalizumab | 70 | 4.5 | 4.5 |
| Sevoflurane | 3 | 4.1 | 4.1 |
| Venetoclax | 22 | 4.1 | 4.1 |
| Sevelamer Carbonate | 4 | 3.9 | 3.9 |
| Bosutinib | 3 | 3.8 | 3.8 |
| Abiraterone Acetate | 11 | 3.0 | 3.0 |
| Dalfampridine | 19 | 3.0 | 3.0 |
| Enzalutamide | 15 | 2.9 | 2.9 |
| Apalutamide | 3 | 2.9 | 2.9 |
| Pimavanserin Tartrate | 12 | 2.5 | 2.5 |
| Evolocumab | 20 | 1.4 | 1.4 |
| Cinacalcet Hydrochloride | 5 | 1.2 | 1.2 |